Literature DB >> 26506117

Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue - Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up.

Quentin Delefortrie1, Patricia Schatt2, Alexandre Grimmelprez2, Patrick Gohy2, Didier Deltour2, Geneviève Collard3, Patrick Vankerkhoven2.   

Abstract

BACKGROUND: Although colonoscopy associated with histopathological sampling remains the gold standard in the diagnostic and follow-up of inflammatory bowel disease (IBD), calprotectin is becoming an essential biomarker in gastroenterology. The aim of this work is to compare a newly developed kit (Liaison® Calprotectin - Diasorin®) and its two distinct extraction protocols (weighing and extraction device protocol) with a well established point of care test (Quantum Blue® - Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn's population in follow-up.
METHODS: Stool specimens were collected over a six month period and were composed of control and Crohn's patients. Amongst the Crohn's population disease activity (active vs quiescent) was evaluated by gastroenterologists.
RESULTS: A significant difference was found between all three procedures in terms of calprotectin measurements (weighing protocol=30.3μg/g (median); stool extraction device protocol=36.9μg/g (median); Quantum Blue® (median)=63; Friedman test, P value=0.05). However, a good correlation was found between both extraction methods coupled with the Liaison® analyzer and between the Quantum Blue® (weighing protocol/extraction device protocol Rs=0.844, P=0.01; Quantum Blue®/extraction device protocol Rs=0.708, P=0.01; Quantum Blue®/weighing protocol, Rs=0.808, P=0.01). Finally, optimal cut-offs (and associated negative predictive values - NPV) for detecting relapses were in accordance with above results (Quantum Blue® 183.5μg/g and NPV of 100%>extraction device protocol+Liaison® analyzer 124.5μg/g and NPV of 93.5%>weighing protocol+Liaison® analyzer 106.5μg/g and NPV of 95%).
CONCLUSIONS: Although all three methods correlated well and had relatively good NPV in terms of detecting relapses amongst a Crohn's population in follow-up, the lack of any international standard is the origin of different optimal cut-offs between the three procedures.
Copyright © 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calprotectin; Crohn's disease follow-up; Crohn's disease relapse screening; Inflammatory bowel disease; Liaison® Calprotectin; Quantum Blue®

Mesh:

Substances:

Year:  2015        PMID: 26506117     DOI: 10.1016/j.clinbiochem.2015.10.010

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  5 in total

Review 1.  Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review.

Authors:  T S Chew; J C Mansfield
Journal:  Frontline Gastroenterol       Date:  2016-04-05

2.  Assessment of the usefulness of imaging studies and biomarkers in the activity of Crohn's disease.

Authors:  Grażyna Piotrowicz; Agnieszka Klufczyńska; Piotr Banaszkiewicz; Łukasz Dorosz; Grażyna Rydzewska
Journal:  Prz Gastroenterol       Date:  2020-03-09

3.  Analytical and clinical performance of the fully-automated LIAISONXL calprotectin immunoassay from DiaSorin in IBD patients.

Authors:  R Vicente-Steijn; J M Jansen; R Bisheshar; I-A Haagen
Journal:  Pract Lab Med       Date:  2020-06-24

4.  Point-of-care Intestinal Ultrasound in IBD Patients: Disease Management and Diagnostic Yield in a Real-world Cohort and Proposal of a Point-of-care Algorithm.

Authors:  S Bots; F De Voogd; M De Jong; V Ligtvoet; M Löwenberg; M Duijvestein; C Y Ponsioen; G D'Haens; K B Gecse
Journal:  J Crohns Colitis       Date:  2022-05-10       Impact factor: 10.020

5.  Evaluation of a fluorescent immunochromatography test for fecal calprotectin.

Authors:  Runqing Li; Xiuying Zhao; Jingxiao Dong; Dong Zhu; Tengjiao Wang; Song Yang; Zhipeng Zhao; Nan Xiao
Journal:  J Clin Lab Anal       Date:  2019-10-06       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.